Repatha and Warfarin Interaction: What Patients and Prescribers Need to Know

The direct answer

Because evolocumab is metabolized via proteolytic degradation and warfarin is cleared mainly through CYP2C9, they do not compete for the same metabolic pathway. No pharmacokinetic interaction is expected between them based on their distinct elimination mechanisms, and post-marketing surveillance has not identified any clinical signals of interaction. This assessment reflects the drugs' different structures and clearance routes rather than results from a dedicated interaction study. Patients taking both medications should continue routine INR monitoring and report all new drugs to their healthcare provider, as warfarin interacts significantly with many other agents despite having no known interaction with evolocumab.

Why this question comes up

Warfarin is one of the more interaction-prone drugs in routine use, and even small changes in its clearance can push the INR outside a safe range. Drugs that inhibit CYP2C9, the enzyme mainly responsible for clearing the more potent S-warfarin enantiomer, are the classic culprits (amiodarone, fluconazole, and metronidazole are well known examples). Patients starting evolocumab for elevated LDL-cholesterol are frequently also on warfarin for atrial fibrillation, a mechanical heart valve, or a prior venous thromboembolism, so asking about interaction risk is reasonable due diligence, not overcaution.

How each drug is cleared, and why that matters

Evolocumab is a fully human IgG2 monoclonal antibody that binds PCSK9. Like other therapeutic antibodies, it is far too large to act as a substrate for cytochrome P450 enzymes or for transporters such as P-glycoprotein. It is eliminated the way endogenous antibodies are, through receptor-mediated uptake and intracellular proteolysis, not through hepatic oxidative metabolism. This is a general pharmacologic property of monoclonal antibodies as a class, not something unique to evolocumab, and it is the reason regulators generally do not require standard CYP-based drug interaction studies for this drug class.

The current FDA-approved prescribing information for Repatha addresses drug interactions briefly, noting that formal interaction studies were not required for a monoclonal antibody of this kind. Editors and clinicians should confirm the exact current wording against the live label before quoting it, since label text can be revised.

Warfarin, by contrast, is a racemic small molecule. The more potent S-enantiomer is cleared mainly by CYP2C9, and the less potent R-enantiomer by CYP1A2 and CYP3A4. Warfarin also binds heavily to plasma albumin, so drugs that displace it from protein binding, or that compete for the same CYP enzymes, are the ones that move the INR. Evolocumab does none of these things: it does not bind albumin the way small molecules do, it does not compete for CYP2C9 active sites, and it has no known effect on platelet function, clotting factor synthesis, or vitamin K metabolism.

Because the two drugs are cleared through entirely separate biological systems, there is no plausible mechanism, pharmacokinetic or pharmacodynamic, through which evolocumab could change warfarin's anticoagulant effect, or vice versa.

What the trial and surveillance evidence adds

The FOURIER cardiovascular outcomes trial tested evolocumab against placebo, on top of statin therapy, in a large population with established atherosclerotic disease, and its published safety analysis did not identify a bleeding signal associated with evolocumab overall. Some FOURIER participants were on background anticoagulants, but the publicly available reporting does not appear to include a dedicated subgroup analysis isolating warfarin users specifically, and any precise bleeding-rate figures for that subgroup should be verified against the original trial publication before being cited in patient materials. The open-label OSLER extension studies followed evolocumab-treated patients for extended periods without a described excess-bleeding signal, though again, exact patient counts and follow-up durations should be checked against the primary source rather than repeated from memory.

The FDA's public FAERS dashboard is the appropriate place to check for any emerging post-marketing reports involving evolocumab and warfarin co-administration, and it should be queried directly rather than summarized from a secondary source (FAERS public dashboard).

Major drug interaction databases (Lexicomp, Micromedex, and similar clinical decision-support tools) generally classify evolocumab and warfarin as having no known interaction. This is consistent with the mechanistic reasoning above, but it reflects an absence of evidence for an interaction rather than a large dedicated safety study proving equivalence.

Evidence-status assessment: evolocumab plus warfarin

Evidence boundary: what is established, what is not

What is established: evolocumab's clearance mechanism (receptor-mediated uptake and intracellular proteolysis) and warfarin's clearance mechanism (CYP2C9-dominant oxidative metabolism) are well documented and operate through entirely different biological systems. That structural fact is the strongest basis for expecting no interaction.

What is plausible but not proven by a dedicated study: that co-administration is clinically safe in the specific population of patients on stable warfarin therapy who start evolocumab, based on the absence of a bleeding signal in evolocumab's broader safety database and the absence of a documented interaction in standard drug-interaction references.

What is not established: any warfarin-specific randomized trial or large prospective cohort designed to test this exact combination. Absence of a reported signal in general trial safety data and absence of a listing in interaction databases is meaningful reassurance, but it is not the same as a dedicated study confirming safety in this pairing.

Practical guidance for patients and prescribers

Repatha injections can be given on any day relative to a warfarin dose; there is no pharmacologic reason to separate the timing of the two. Starting or stopping evolocumab does not, on its own, warrant extra INR testing beyond the patient's existing anticoagulation monitoring schedule. If a prescriber does order additional INR checks around the time evolocumab is started, it is worth asking whether that is because of a simultaneous statin change rather than the evolocumab itself, since some statins (unlike evolocumab) can modestly affect INR through CYP2C9 competition and are a more plausible source of any observed INR shift.

Patients on warfarin may notice more bruising at an injection site simply because they are anticoagulated, which is a local effect of warfarin, not a drug-drug interaction with evolocumab. Patients using a direct oral anticoagulant such as apixaban or rivaroxaban instead of warfarin are not expected to have a different interaction profile with evolocumab, since these agents are cleared through CYP3A4 and P-glycoprotein pathways that a monoclonal antibody does not touch, though this reasoning is also mechanistic rather than trial-confirmed.

Neither drug should be stopped without talking to the prescribing clinician. Stopping warfarin changes thromboembolic risk that is usually being actively managed (for atrial fibrillation, a mechanical valve, or prior clot), and stopping evolocumab allows LDL-cholesterol to drift back toward pretreatment levels over subsequent weeks. These are two separate clinical decisions with two separate risk calculations, and the fact that the drugs do not interact does not by itself answer whether either one is still the right choice for a given patient.

When to reconsider the combination, not because of interaction risk

For a patient stable on both warfarin and evolocumab, the question worth revisiting periodically is not whether the drugs are safe together, but whether each is still indicated on its own terms. Warfarin candidates for atrial fibrillation or venous thromboembolism are sometimes appropriate for conversion to a direct oral anticoagulant, which can simplify monitoring; that decision depends on the underlying indication, not on evolocumab. Evolocumab's continued use depends on whether LDL-cholesterol and cardiovascular risk goals under current guideline-based care still support a PCSK9 inhibitor, particularly for patients who have been at goal for an extended period. Cost and insurance coverage for evolocumab are frequently a bigger practical barrier to combination therapy than any safety concern, and current pricing should be checked directly with the pharmacy or payer rather than assumed from a prior year's figure.

When to seek urgent care

Bruising, unusual bleeding, blood in urine or stool, severe headache, or signs of a stroke in a patient on warfarin warrant urgent evaluation regardless of whether the patient is also on evolocumab, because these are warfarin-related warning signs, not signs specific to a Repatha interaction. A rash, hives, facial or throat swelling, or difficulty breathing after a Repatha injection should also prompt urgent care, since hypersensitivity reactions are a recognized class effect of monoclonal antibodies, separate from any anticoagulant interaction question.